Bicalutamid-Teva 50 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bicalutamid-teva 50 mg

teva pharmaceuticals slovakia s.r.o., slovensko - bikalutamid - 44 - cytostatica

Bicalutamid-Teva 150 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bicalutamid-teva 150 mg

teva pharmaceuticals slovakia s.r.o., slovensko - bikalutamid - 44 - cytostatica

Bicusan 150 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bicusan 150 mg

actavis group ptc ehf., island - bikalutamid - 44 - cytostatica

Bicacel 150 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bicacel 150 mg

glenmark pharmaceuticals s.r.o., Česká republika - bikalutamid - 44 - cytostatica

Caprodez Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

caprodez

ardez pharma, spol. s r.o., Česká republika - bikalutamid - 44 - cytostatica

Xtandi Európska únia - slovenčina - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatické nádory - endokrinná terapia - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.